drugset

drugset / Trial / NCT00186420

Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation

NCT00186420 ↗

Phase 2 Completed 13 enrolled Stanford University Aventis Pharmaceuticals · collab

Non-randomizedSingle-groupOpen-labelPrevention

Summary

The purpose of this study is to evaluate time to progression (TTP) by PSA in patients with high risk prostate cancer after definitive therapy.

Timeline

Start: 2003-07
Primary completion: 2006-01
Completion: 2009-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Docetaxel	Small molecule	—	—

Indications